Literature DB >> 22717289

Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study.

Camilo de la Fuente-Sandoval1, Pablo León-Ortiz, Mariana Azcárraga, Rafael Favila, Sylvana Stephano, Ariel Graff-Guerrero.   

Abstract

Increased glutamate levels in the associative-striatum have been described in subjects at ultra-high risk for psychosis (UHR); nevertheless, it is unclear whether this abnormality predicts the conversion to psychosis. Nineteen subjects at UHR and 26 controls were studied using proton magnetic resonance spectroscopy. Subjects at UHR were clinically followed for 2 yr. Seven UHR subjects (37%) transitioned to a psychotic disorder and the remaining 12 did not exhibit psychotic symptoms at the most recent follow-up. The psychosis transition group had higher glutamate levels compared to both non-transition and control groups (p = 0.02 and p < 0.01, respectively; effect size 1.39). These pilot findings suggest that the conversion to psychosis is associated with increased glutamate levels in the associative-striatum.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22717289     DOI: 10.1017/S1461145712000314

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  38 in total

Review 1.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

2.  Interactions between glutamate, dopamine, and the neuronal signature of response inhibition in the human striatum.

Authors:  Robert C Lorenz; Tobias Gleich; Ralph Buchert; Florian Schlagenhauf; Simone Kühn; Jürgen Gallinat
Journal:  Hum Brain Mapp       Date:  2015-07-14       Impact factor: 5.038

3.  Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients.

Authors:  Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Xiangling Mao; Pablo León-Ortiz; Oscar Rodríguez-Mayoral; Helgi Jung-Cook; Rodolfo Solís-Vivanco; Ariel Graff-Guerrero; Dikoma C Shungu
Journal:  Biol Psychiatry       Date:  2017-10-10       Impact factor: 13.382

4.  Ultrastructural evidence for glutamatergic dysregulation in schizophrenia.

Authors:  Rosalinda C Roberts; Lesley A McCollum; Kirsten E Schoonover; Samuel J Mabry; Joy K Roche; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2020-01-31       Impact factor: 4.939

Review 5.  Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

Authors:  Eline M P Poels; Lawrence S Kegeles; Joshua T Kantrowitz; Daniel C Javitt; Jeffrey A Lieberman; Anissa Abi-Dargham; Ragy R Girgis
Journal:  Schizophr Res       Date:  2014-01-11       Impact factor: 4.939

Review 6.  Biomarkers in psychosis: an approach to early identification and individualized treatment.

Authors:  Heline Mirzakhanian; Fiza Singh; Kristin S Cadenhead
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

7.  Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL study.

Authors:  S Andrea Wijtenburg; Susan N Wright; Stephanie A Korenic; Frank E Gaston; Nkemdilim Ndubuizu; Joshua Chiappelli; Robert P McMahon; Hongji Chen; Anya Savransky; Xiaoming Du; Danny J J Wang; Peter Kochunov; L Elliot Hong; Laura M Rowland
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

8.  Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium.

Authors:  Tracy Alderman; Jean Addington; Carrie Bearden; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Kristin S Cadenhead
Journal:  Early Interv Psychiatry       Date:  2014-02-27       Impact factor: 2.732

9.  Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.

Authors:  Eric Plitman; Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Sofia Chavez; Gladys Gómez-Cruz; Pablo León-Ortiz; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2015-08-28       Impact factor: 9.306

10.  Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study.

Authors:  Camilo de la Fuente-Sandoval; Pablo León-Ortiz; Mariana Azcárraga; Sylvana Stephano; Rafael Favila; Leonardo Díaz-Galvis; Patricia Alvarado-Alanis; Jesús Ramírez-Bermúdez; Ariel Graff-Guerrero
Journal:  JAMA Psychiatry       Date:  2013-10       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.